Intellect Neurosciences CEO Daniel Chain to Discuss Vaccine Program at Alzheimer's Drug Development Summit

company logo

NEW YORK, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will discuss Intellect's vaccine program at the Alzheimer's Drug Development Summit on December 11-12, 2012 at the Doubletree Center City in Philadelphia, PA where he has been invited as a Distinguished Speaker.

Dr. Chain's presentation, titled "Recent Advancements in Vaccine Development for AD Prophylaxis and Management," begins at 2:15 PM (EST) on December 12. The presentation reviews the challenges associated with the development of a safe and effective Alzheimer's vaccine and describes the rationale in support of Intellect's ground-breaking approach. The company's lead vaccine, RV03, is a first-in-class chimeric peptide vaccine targeting both amyloid beta and delta tau, a particularly pathogenic form of the protein that precedes tangle formation.

"Some suggest that disease-modifying treatments of Alzheimer's disease may ultimately be more expensive than palliative care," said Dr. Chain. "Therefore, the utility of a vaccine for Alzheimer's disease may prove to be the most cost-effective means to manage the disease and alleviate the suffering of millions of people and their families worldwide while also reducing the burden to healthcare systems."

About Intellect Neurosciences

Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit

The Intellect Neurosciences, Inc. logo is available at

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-‐looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Quarterly Report on Form 10-Q (file no. 333-‐128226), filed on November 20, 2012.

CONTACT: Jules Abraham JQA Partners, LLC 917-885-7378

Source:Intellect Neurosciences, Inc.